NZ569949A - Sublingual fentanyl spray - Google Patents

Sublingual fentanyl spray

Info

Publication number
NZ569949A
NZ569949A NZ569949A NZ56994907A NZ569949A NZ 569949 A NZ569949 A NZ 569949A NZ 569949 A NZ569949 A NZ 569949A NZ 56994907 A NZ56994907 A NZ 56994907A NZ 569949 A NZ569949 A NZ 569949A
Authority
NZ
New Zealand
Prior art keywords
fentanyl
formulation
sublingual
dose
pharmaceutically acceptable
Prior art date
Application number
NZ569949A
Other languages
English (en)
Inventor
S George Kottayil
Venkat R Goskonda
Zhongyuan Zhu
Linet Kattookaran
Neha N Parikh
Original Assignee
Insys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38309867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ569949(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insys Therapeutics Inc filed Critical Insys Therapeutics Inc
Publication of NZ569949A publication Critical patent/NZ569949A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ569949A 2006-01-25 2007-01-25 Sublingual fentanyl spray NZ569949A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76205706P 2006-01-25 2006-01-25
PCT/US2007/002163 WO2007087431A2 (en) 2006-01-25 2007-01-25 Sublingual fentanyl spray

Publications (1)

Publication Number Publication Date
NZ569949A true NZ569949A (en) 2011-10-28

Family

ID=38309867

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ569949A NZ569949A (en) 2006-01-25 2007-01-25 Sublingual fentanyl spray

Country Status (16)

Country Link
US (6) US8486972B2 (enExample)
EP (2) EP2641595A1 (enExample)
JP (3) JP5241514B2 (enExample)
CN (1) CN101378735B (enExample)
AU (1) AU2007208229B2 (enExample)
BR (1) BRPI0707235B8 (enExample)
CA (1) CA2637672C (enExample)
DK (1) DK1976521T3 (enExample)
ES (1) ES2535233T3 (enExample)
MX (3) MX374396B (enExample)
NZ (1) NZ569949A (enExample)
PL (1) PL1976521T3 (enExample)
PT (1) PT1976521E (enExample)
RU (1) RU2432950C2 (enExample)
SI (1) SI1976521T1 (enExample)
WO (1) WO2007087431A2 (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE388705T1 (de) 2000-07-31 2008-03-15 Nycomed Danmark Aps Fentanyl zusammensetzung zur nasalen anwendung
RU2432950C2 (ru) 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
US8210167B2 (en) * 2007-03-02 2012-07-03 Corbco, Inc. Manually operated monodose nasal sprayer
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
ES2668366T3 (es) * 2007-08-02 2018-05-17 Insys Development Company, Inc. Pulverización sublingual de fentanilo
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
WO2009094459A1 (en) * 2008-01-22 2009-07-30 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
KR101564058B1 (ko) 2009-02-26 2015-10-29 테이코쿠 팔마 유에스에이, 인코포레이티드 암 통증 치료용 마취 유상액 제제
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
JP2012524771A (ja) * 2009-04-23 2012-10-18 ロンドンファーマ リミテッド 中性油を含む舌下用の医薬組成物
AU2010248776B2 (en) * 2009-05-15 2013-06-06 Baudax Bio, Inc. Sublingual dexmedetomidine compositions and methods of use thereof
US20120214874A1 (en) * 2009-08-26 2012-08-23 Nuvo Research Inc. Pharmaceutical formulations and methods of use
US20130202654A1 (en) * 2009-11-23 2013-08-08 Cipla Limited Topical Foam Composition
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
GB2481728B (en) * 2010-06-30 2012-05-23 Londonpharma Ltd Formulations and delivery devices for the sublingual administration of opioids
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
GB2487007B (en) * 2012-03-19 2013-06-05 Londonpharma Ltd COC containers and delivery devices for the sublingual administration of opioids
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
WO2015038327A1 (en) 2013-09-10 2015-03-19 Insys Pharma, Inc. Sublingual buprenorphine spray
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US9566233B2 (en) 2013-11-14 2017-02-14 Insys Development Company, Inc. Ondansetron sublingual spray formulation
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9855234B2 (en) * 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
JP2017519803A (ja) * 2014-07-08 2017-07-20 インシス・ファーマ・インコーポレーテッド 舌下ナロキソンスプレー
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
CN120114438A (zh) * 2016-04-13 2025-06-10 内布拉斯加大学董事会 施用树脂毒素的方法和用树脂毒素治疗心血管疾病的方法
US20170340557A1 (en) * 2016-05-27 2017-11-30 Insys Development Company, Inc. Sublingual fentanyl formulations containing a permeation enhancer
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
AU2021217164A1 (en) * 2020-02-05 2022-08-25 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244478A (en) 1979-06-27 1981-01-13 Mpl, Inc. Closure assembly for unit dose vial
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5219083A (en) 1992-04-02 1993-06-15 Sterling Winthrop Inc. Stopper for reduction of particulate matter
ATE173396T1 (de) * 1993-08-10 1998-12-15 Boots Co Plc Spruehformulierung mit kuehleffekt
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050180923A1 (en) 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20050287075A1 (en) 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
WO1999016417A1 (en) 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
US20030077228A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20050002867A1 (en) 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
US20040136913A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20040141923A1 (en) 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20090162300A1 (en) 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
WO2000047203A1 (en) 1999-02-12 2000-08-17 Mqs, Inc. Formulation and system for intra-oral delivery of pharmaceutical agents
EP1296649A2 (en) * 2000-06-22 2003-04-02 Pharmasol Limited Pharmaceutical compositions comprising an opioid analgesic
WO2002045713A2 (en) 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
EP1599186B1 (en) * 2003-02-24 2013-04-10 Pharmaceutical Productions Inc. Transmucosal drug delivery system
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
AU2004218876B2 (en) * 2003-03-11 2007-08-02 Arakis Ltd. Novel compositions containing fentanyl
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
US20070124554A1 (en) * 2005-10-28 2007-05-31 Honeywell International Inc. Global memory for a rapidio network
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
RU2432950C2 (ru) 2006-01-25 2011-11-10 Инсис Терапьютикс Инк. Подъязычный спрей на основе фентанила
ES2668366T3 (es) * 2007-08-02 2018-05-17 Insys Development Company, Inc. Pulverización sublingual de fentanilo

Also Published As

Publication number Publication date
JP5630877B2 (ja) 2014-11-26
WO2007087431A3 (en) 2008-09-25
PL1976521T3 (pl) 2015-10-30
BRPI0707235B1 (pt) 2020-04-14
RU2432950C2 (ru) 2011-11-10
US8835460B2 (en) 2014-09-16
CN101378735B (zh) 2013-04-03
US20140343100A1 (en) 2014-11-20
JP2013127003A (ja) 2013-06-27
US20070261695A1 (en) 2007-11-15
US9642797B2 (en) 2017-05-09
CA2637672A1 (en) 2007-08-02
BRPI0707235B8 (pt) 2021-05-25
US10016403B2 (en) 2018-07-10
US20170202820A1 (en) 2017-07-20
CN101378735A (zh) 2009-03-04
EP2641595A1 (en) 2013-09-25
ES2535233T3 (es) 2015-05-06
US20130327321A1 (en) 2013-12-12
RU2008130763A (ru) 2010-02-27
MX2020008616A (es) 2020-09-21
PT1976521E (pt) 2015-06-09
MX2008009522A (es) 2009-01-07
EP1976521B1 (en) 2015-03-11
BRPI0707235A2 (pt) 2011-04-26
CA2637672C (en) 2012-07-24
JP2013056928A (ja) 2013-03-28
WO2007087431A2 (en) 2007-08-02
US20180303813A1 (en) 2018-10-25
US8486972B2 (en) 2013-07-16
DK1976521T3 (en) 2015-04-27
US20160193142A1 (en) 2016-07-07
US9289387B2 (en) 2016-03-22
EP1976521A2 (en) 2008-10-08
JP2009528272A (ja) 2009-08-06
EP1976521A4 (en) 2010-11-03
AU2007208229A1 (en) 2007-08-02
MX374396B (es) 2025-03-06
SI1976521T1 (sl) 2015-06-30
AU2007208229B2 (en) 2009-11-05
JP5241514B2 (ja) 2013-07-17

Similar Documents

Publication Publication Date Title
NZ569949A (en) Sublingual fentanyl spray
US10610523B2 (en) Sublingual fentanyl spray
DK2643092T3 (en) Cyclic product supply by a centrifuge and centrifuge thereto
HK1189809A (en) Sublingual fentanyl spray

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 25 JAN 2017 BY COMPUTER PACKAGES INC

Effective date: 20140128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JAN 2018 BY COMPUTER PACKAGES INC

Effective date: 20170118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JAN 2019 BY COMPUTER PACKAGES INC

Effective date: 20180118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JAN 2020 BY COMPUTER PACKAGES INC

Effective date: 20190118

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JAN 2021 BY COMPUTER PACKAGES INC

Effective date: 20191231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 25 JAN 2022 BY COMPUTER PACKAGES INC

Effective date: 20201231

LAPS Patent lapsed